Area of research
Pulmonary and Respiratory Medicine · Biomedical Engineering
Research interest
Research interests include Photodynamic Therapy Research Studies, Nanoplatforms for cancer theranostics, Diatoms and Algae Research, and Bladder and Urothelial Cancer Treatments.
Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
Impact of Approach Routes in MRI-Ultrasound Fusion Prostate Biopsy on Post-Biopsy Complications: A Propensity Score-Matched Analysis.
Bayesian Reanalysis of Adjuvant Nivolumab in Japanese Patients With High-Risk Muscle-Invasive Urothelial Carcinoma.
Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
Bayesian interpretation of febrile neutropenia risk and primary granulocyte colony-stimulating factor prophylaxis during darolutamide triplet therapy.
Understanding tumor microenvironment dynamics and immune checkpoint inhibitor efficacy following mEGFR-targeted near-infrared photoimmunotherapy
Editorial Comment on Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.
Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer.
Bayesian Re-Interpretation of the CheckMate-9ER Final Analysis: Organ-Site and IMDC Risk-Stratified Probabilities of Benefit.
Bayesian Multi-Criteria Decision Analysis of Net Clinical Benefit in ARASENS: Overall and Japanese Subgroup Results.
Translational Advances in Urothelial Carcinoma: From Bench to Bedside.
Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.
Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Time-Dependent Analysis of Reconstructed Individual Patient Data From the PEACE-3 Trial.
Antitumor host immunity enhanced by near-infrared photoimmunotherapy.
Carbonic anhydrase-9-targeted near-infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma.
Impact of Vitamin C on Immune Response and Edema Following Near-Infrared Photoimmunotherapy (NIR-PIT).
Impact of Impaired Renal Function on the Efficacy and Safety of Enfortumab Vedotin Monotherapy in a Multicenter Real-World Cohort of Patients With Metastatic Urothelial Cancer: YUSHIMA Study.
Figure S13 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S5 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Data from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S1 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S12 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S9 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S10 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S6 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Table S1 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S2 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S4 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S8 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Figure S3 from Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy